On the Impossible

12/18/2024 - In this work, I will prove why belapectin--the only drug in the Galectin Therapeutics portfolio--does not work, and why it is impossible for the upcoming Phase II/III study in NASH to meet its primary endpoint. Galectin has nearly no cash remaining.

In this work, I will prove why simufilam does not work, and why it is impossible for the Phase III studies of simufilam in Alzheimers to meet their primary endpoints. Cassava has $3/share in cash and is presently trading for $32.00. Simufilam is Cassavas sole asset.